Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Langone Health’s Perlmutter Cancer Center, addresses the need for additional predictive biomarkers for non-small cell lung cancer (NSCLC) patients with no known driver mutation. Dr. Sabari says, to date, PD-L1 is the only effective biomarker, with increased PD-L1 being predictive of better patient outcomes. While TMB was initially thought to be a suitable candidate, the CheckMate-227 data indicated TMB is only a prognostic biomarker. In the future, Dr. Sabari hopes to see additional biomarkers discovered to inform better immunotherapeutic treatment.

Learn more by clicking here.